Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ICOSLG drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ICOSLG ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ICOSLG Products |
| Gene Delivery | ICOSLG Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ICOSLG Products |
| Benchmark Ab | Anti-ICOSLG (Sequence of Benchmark) Recombinant positive control. |
View ICOSLG Products |
| Validator | ICOSLG siRNA Set For knockdown verification. |
View ICOSLG Products |
| Related Target A | ICOS The sole physiological receptor for ICOSLG, essential for binding assays. |
View ICOS Products |
| Related Target B | PD-L1 Synergistic immune checkpoint for combination therapy or bispecific design. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Receptor Specificity (B7 Family) | Ensures exclusive ICOS binding; free of off-target CD28/CTLA-4 artifacts |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ICOSLG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ICOSLG therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and immunomodulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise modulation of the ICOS-ICOSLG axis for both solid tumors (agonism/activation) and autoimmune diseases (blockade).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Amgen, GSK | Solid Tumors / SLE | Binding Affinity (Need high-purity ECD-Fc) |
| Bispecific (e.g., PD-L1 x ICOSLG) | Biotest, MedImmune | Advanced Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| Recombinant Fusion Proteins | Various Biotechs | Autoimmune Disorders | Receptor Specificity Assay (Need Native Glycosylation) |